Ruxience
Ruxience ingredients
| Active ingredient | Strength |
|---|---|
| Rituximab | 500 mg/50mL, 100 mg/10mL |
What Ruxience is used for
The FDA lists the approved uses on the official label (below). In the EU, rituximab is approved as MabThera for:
MabThera is indicated in adults for the following indications: Non Hodgkin’s lymphoma (NHL) MabThera is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy. MabThera maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. MabThera monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged … (the exact …
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ruxience
- Generic name
- Rituximab-pvvr
- Made by
- Pfizer Laboratories Div Pfizer Inc
- Forms
- Injection, Solution
- Given
- Intravenous
- Drug class
- CD20-directed Cytolytic Antibody
- FDA approval
- Biologic licence (BLA) BLA761103
- On the US market since
- 2020
Official information
- MedlinePlus drug information (search for Rituximab-pvvr)
In India
- Rituximab: 37 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ruxience?
Ruxience (Rituximab-pvvr) is a cancer medicine made by Pfizer Laboratories Div Pfizer Inc, approved by the US FDA.
What are the ingredients of Ruxience?
Ruxience contains Rituximab (500 mg/50mL, 100 mg/10mL).
Is Ruxience approved in Europe?
The same active substance is approved in the EU as MabThera.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA